KAI-1678, First-in-Class Compound, Enters Phase 2a Clinical Testing For The Treatment Of Pain

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced the Company has initiated enrollment in a Phase 2a clinical study of KAI-1678 in patients with moderate to severe postoperative pain following total hip or total knee replacement. KAI-1678, a first-in-class, isozyme-selective, small peptide inhibitor of the epsilon protein kinase C pathway (epsilon PKC), has been shown to be safe and well-tolerated in Phase 1 testing.

More: continued here

Filed under: Pain / Anesthetics on December 19th, 2008